pharma · Diabetes Mellitus, Type 2 · Pharmacokinetic trial
Boehringer Ingelheim
Boehringer Ingelheim clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Binger Straße, Ingelheim am Rhein, Rhineland-Palatinate 55218, DE
- Employees
- 46,699
- Programs
- 193
- Drugs
- 113
- Patents
- 25
Boehringer Ingelheim projects
6 ClinicalTrials.gov programs sponsored by Boehringer Ingelheim.
Boehringer Ingelheim has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Afatinib
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
Spesolimab
Boehringer Ingelheim
Generalized Pustular Psoriasis
3 trials -
Telmisartan
Boehringer Ingelheim
Cardiovascular Diseases
1 trial -
metformin
Boehringer Ingelheim
Diabetes Mellitus, Type 2
1 trial -
telmisartan
Boehringer Ingelheim
Hypertension
1 trial -
tiotropium 18 mcg
Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
1 trial
Frequently asked questions
How many clinical projects does Boehringer Ingelheim have?
6 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.